Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;34(1):e14647.
doi: 10.1111/dth.14647. Epub 2020 Dec 15.

Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?

Tugba Kevser Uzuncakmak  1 , Defne Özkoca  1 , Ozge Askin  1 , Zekayi Kutlubay  1
Affiliations

Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?

Tugba Kevser Uzuncakmak et al. Dermatol Ther. 2021 Jan.

Abstract

Rituximab is a monoclonal antibody that targets CD20, a B-lymphocyte antigen; that leads to a decline in the B-cell counts for at least a year. The patients who have received rituximab treatment in the previous 5 years with the diagnosis of pemphigus group of diseases at Cerrahpaşa Medical Faculty were questioned for COVID-19 infection. A total of 48 patients were included in this study; only one male patient had COVID-19 infection which had a mild course. There is no significant difference in the total number of lymphocytes between patients who have received rituximab within the previous 5 years or last year. The number of lymphocytes is independent of the number of courses of rituximab treatment received. Therefore, we suggest that all pemphigus patients who have received rituximab treatment within the previous 5 years should be careful of the preventive measures against the COVID-19 infection irrespective of the number of treatment courses or the number of years which has passed since the treatment. The disease course was mild in the only infected patient. Thus, rituximab may be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic if its use is necessary.

Keywords: CD20; COVID-19; lymphocyte; pemphigus; rituximab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baum S, Raviv T, Gilboa S, Pavlotsky F, Barzilai A. Efficacy of repeated courses of rituximab as treatment for pemphigus vulgaris. Acta Dermatol Venereol. 2020;100(17):adv00286 10.2340/00015555-3649. - DOI - PMC - PubMed
    1. Joly P, Horwath B, Patsatsi A, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34:1900‐1913. 10.1111/jdv.16752. - DOI - PubMed
    1. Liu Z, Long W, Tu M, et al. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID‐19. J Infect. 2020;81(2):318‐356. 10.1016/j.jinf.2020.03.054. - DOI - PMC - PubMed
    1. Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford). 2007;46(4):626‐630. 10.1093/rheumatology/kel393. - DOI - PubMed
    1. Murchu OE, Byrne P, Walsh KA, et al. Immune response following infection with SARS‐CoV‐2 and other coronaviruses: a rapid review. Rev Med Virol. 2020;e2162 10.1002/rmv.2162. - DOI - PMC - PubMed